| Literature DB >> 32648341 |
Min Xu1, Fei Zhang1, Zhuo Cheng1, Ghader Bashiri2, Jing Wang1, Jiali Hong1, Yemin Wang1, Lijun Xu1, Xuefei Chen1, Sheng-Xiong Huang3, Shuangjun Lin1, Zixin Deng1, Meifeng Tao1.
Abstract
Lantibiotics are a type of ribosomally synthesized and post-translationally modified peptides (termed lanthipeptides) with often potent antimicrobial activity. Herein, we report the discovery of a new lantibiotic, lexapeptide, using the library expression analysis system (LEXAS) approach. Lexapeptide has rare structural modifications, including N-terminal (N,N)-dimethyl phenylalanine, C-terminal (2-aminovinyl)-3-methyl-cysteine, and d-Ala. The characteristic lanthionine moiety in lexapeptide is formed by three proteins (LxmK, LxmX, and LxmY), which are distinct from enzymes known to be involved in lanthipeptide biosynthesis. Furthermore, a novel F420 H2 -dependent reductase (LxmJ) from the lexapeptide biosynthetic gene cluster (BGC) is identified to catalyze the reduction of dehydroalanine to install d-Ala. Our findings suggest that lexapeptide is the founding member of a new class of lanthipeptides that we designate as class V. We also identified further class V lanthipeptide BGCs in actinomycetes and cyanobacteria genomes, implying that other class V lantibiotics await discovery.Entities:
Keywords: F420H2 reductase; biosynthesis; class V lanthionine synthetase; lanthipeptide; lexapeptide
Mesh:
Substances:
Year: 2020 PMID: 32648341 DOI: 10.1002/anie.202008035
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336